Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 10,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $53.76 on Friday. The company’s 50 day simple moving average is $50.16 and its two-hundred day simple moving average is $54.00. The stock has a market capitalization of $6.84 billion, a PE ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Analyst Ratings Changes

HALO has been the topic of a number of recent analyst reports. Piper Sandler lifted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently added to or reduced their stakes in the business. First Hawaiian Bank increased its stake in Halozyme Therapeutics by 56.2% in the 4th quarter. First Hawaiian Bank now owns 57,550 shares of the biopharmaceutical company’s stock worth $2,751,000 after acquiring an additional 20,700 shares during the last quarter. Oliver Luxxe Assets LLC raised its stake in Halozyme Therapeutics by 5.6% in the fourth quarter. Oliver Luxxe Assets LLC now owns 29,325 shares of the biopharmaceutical company’s stock valued at $1,402,000 after purchasing an additional 1,555 shares in the last quarter. Everence Capital Management Inc. bought a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $244,000. Retirement Systems of Alabama grew its stake in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after buying an additional 74,173 shares in the last quarter. Finally, Castellan Group increased its holdings in shares of Halozyme Therapeutics by 4.5% in the 3rd quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock worth $6,514,000 after buying an additional 4,876 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.